We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-11.09%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.96B
AUM Growth
-$1.12B
Cap. Flow
-$87.3M
Cap. Flow %
-2.94%
Top 10 Hldgs %
72.49%
Holding
61
New
8
Increased
6
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$239M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$205M
3
MRSN
Mersana Therapeutics
MRSN
+$36.8M
4
ARVN icon
Arvinas
ARVN
+$35.6M
5
SLRN
ACELYRIN
SLRN
+$29.8M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$419M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$124M
3
BPMC
Blueprint Medicines
BPMC
+$114M
4
RVMD icon
Revolution Medicines
RVMD
+$48.1M
5
DYN icon
Dyne Therapeutics
DYN
+$8.99M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
2 Miscellaneous 1.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
1
Prothena Corp
PRTA
$479M
$559M 18.85%
11,584,280
– –
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$415M 13.99%
10,899,859
+5,448,212
+100% +$239M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$250M 8.45%
+5,748,399
New +$205M
LKFT
4
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$199M 6.71%
5,756,268
– –
RVMD icon
5
Revolution Medicines
RVMD
$44.6B
$154M 5.21%
5,577,863
-1,620,837
-23% -$48.1M
ANAB icon
6
AnaptysBio
ANAB
$1.67B
$135M 4.56%
7,521,024
– –
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$5.02B
$125M 4.21%
5,991,479
– –
ARVN icon
8
Arvinas
ARVN
$600M
$107M 3.62%
5,467,063
+1,449,275
+36% +$35.6M
XNCR icon
9
Xencor
XNCR
$1.94B
$106M 3.59%
5,282,516
– –
TNGX icon
10
Tango Therapeutics
TNGX
$3.94B
$98.2M 3.31%
8,721,636
+4,674,522
+116% +$28.5M
ZYME icon
11
Zymeworks
ZYME
$2.02B
$85.2M 2.87%
13,437,473
– –
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
$80M 2.7%
3,460,208
– –
KURA icon
13
Kura Oncology
KURA
$1.13B
$53M 1.79%
5,806,871
– –
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$15.9B
$47.7M 1.61%
368,411
– –
CRNX icon
15
Crinetics Pharmaceuticals
CRNX
$9B
$45.5M 1.54%
1,530,263
+200,000
+15% +$4.12M
CNTA
16
DELISTED
Centessa Pharmaceuticals
CNTA
$36.4M 1.23%
5,618,779
– –
RLAY icon
17
Relay Therapeutics
RLAY
$4.11B
$35M 1.18%
4,163,824
– –
MORF
18
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$33.9M 1.14%
1,480,190
-2,366,774
-62% -$124M
VYGR icon
19
Voyager Therapeutics
VYGR
$218M
$29.8M 1.01%
3,851,507
– –
NMRA icon
20
Neumora Therapeutics
NMRA
$261M
$29.2M 0.99%
+2,071,450
New +$25.9M
APLS
21
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$27.9M 0.94%
+732,500
New +$32.2M
ALEC icon
22
Alector
ALEC
$261M
$26.3M 0.89%
4,056,548
– –
NUVB icon
23
Nuvation Bio
NUVB
$2.34B
$25.7M 0.87%
19,209,643
+5,313,100
+38% +$8.84M
MRSN
24
DELISTED
Mersana Therapeutics
MRSN
$24.6M 0.83%
+774,588
New +$36.8M
OVID icon
25
Ovid Therapeutics
OVID
$547M
$23.5M 0.79%
6,117,400
– –
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2023 Portfolio in Review

As of Q3 2023, EcoR1 Capital held 61 positions worth $2.96B, down 27% from $4.08B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital's Q3 2023 filing shows 8 new, 6 increased, 4 reduced and 10 closed positions. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 5,748,399 shares worth $250M. The largest sale was Sarepta Therapeutics, an estimated $419M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q3 2023 buy was Mirati Therapeutics, Inc. Common Stock: 5,748,399 shares worth $250M.
  • EcoR1 Capital added most to Apellis Pharmaceuticals in Q3 2023, an estimated $239M increase.
  • EcoR1 Capital's biggest Q3 2023 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $124M.
  • EcoR1 Capital fully exited Sarepta Therapeutics in Q3 2023, selling an estimated $419M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $2.96B portfolio in Q3 2023.
  • EcoR1 Capital opened 8 new positions and closed 10 in Q3 2023.
  • EcoR1 Capital's portfolio value fell 27% quarter-over-quarter to $2.96B.

Based on EcoR1 Capital's 13F filing for Q3 2023, filed 14 Nov 2023.